|
| | Publication Year | Title | Author(s) |
| 41 | 22-Apr-2017 | PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected NSCLC | Ameratunga, Malaka; Asadi, Khashayar ; Lin, Xihui; Walkiewicz, Marzena; Murone, Carmel ; Knight, Simon; Mitchell, Paul L R ; Boutros, Paul; John, Thomas |
| 42 | 2017 | The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. | Thapa, Bibhusal ; Salcedo, Adriana; Lin, Xihui; Walkiewicz, Marzena; Murone, Carmel ; Ameratunga, Malaka; Asadi, Khashayar ; Deb, Siddhartha; Barnett, Stephen A ; Knight, Simon; Mitchell, Paul L R ; Watkins, D Neil; Boutros, Paul C; John, Thomas |
| 43 | Dec-2016 | Lung cancer in 2016: immunotherapy comes of age | Mitchell, Paul L R ; John, Thomas |
| 44 | Dec-2016 | Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma. | Thapa, Bibhusal ; Walkiewicz, Marzena; Murone, Carmel ; Asadi, Khashayar ; Deb, Siddhartha; Barnett, Stephen A ; Knight, Simon R ; Mitchell, Paul L R ; Liew, Danny; Watkins, D Neil; John, Thomas |
| 45 | 18-Oct-2016 | Digital PCR of genomic rearrangements for monitoring circulating tumour DNA | Do, Hongdo; Cameron, Daniel; Molania, Ramyar; Thapa, Bibhusal ; Rivall, Gareth; Mitchell, Paul L R ; Murone, Carmel ; John, Thomas ; Papenfuss, Anthony; Dobrovic, Alexander |
| 46 | Aug-2016 | Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment | Chia, Puey Ling ; Do, Hongdo; Morey, Adrienne; Mitchell, Paul L R ; Dobrovic, Alexander ; John, Thomas |
| 47 | Jul-2016 | Combined BRAF and MEK inhibition in BRAF-mutant NSCLC. | Rivalland, Gareth; Mitchell, Paul L R |
| 48 | 21-Jun-2016 | Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. | Gray, H J; Benigno, B; Berek, J; Chang, J; Mason, J; Mileshkin, L; Mitchell, Paul L R ; Moradi, M; Recio, F O; Michener, C M; Secord, A Alvarez; Tchabo, N E; Chan, J K; Young, J; Kohrt, H; Gargosky, S E; Goh, J C |
| 49 | Jun-2015 | Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. | Mitchell, Paul L R ; Thatcher, N; Socinski, M A; Wasilewska-Tesluk, E; Horwood, K; Szczesna, A; Martín, C; Ragulin, Y; Zukin, M; Helwig, C; Falk, M; Butts, C; Shepherd, F A |
| 50 | 1-Apr-2015 | Evolving treatment paradigms in lung cancer: role of immuno-oncology. | Mitchell, Paul L R |
| 51 | 2015 | Update on Mucin-1 immunotherapy in cancer: a clinical perspective | Rivalland, Gareth; Loveland, Bruce E; Mitchell, Paul L R |
| 52 | 20-Nov-2014 | Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. | Chia, Puey Ling ; Mitchell, Paul L R ; Dobrovic, Alexander ; John, Thomas |
| 53 | 18-Jun-2014 | A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer. | Mitchell, Paul L R ; Quinn, Michael A; Grant, Peter; Allen, David G; Jobling, Thomas W; White, Shane C; Zhao, Anne; Karanikas, Vaios; Vaughan, Hilary A; Pietersz, Geoffrey A; McKenzie, Ian F C; Gargosky, Sharron E; Loveland, Bruce E |
| 54 | 26-Feb-2014 | A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. | Do, Hongdo; Wong, Nicholas C; Murone, Carmel ; John, Thomas ; Solomon, Benjamin J; Mitchell, Paul L R ; Dobrovic, Alexander |
| 35 | 9-Dec-2013 | Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. | Butts, Charles; Socinski, Mark A; Mitchell, Paul L R ; Thatcher, Nick; Havel, Libor; Krzakowski, Maciej; Nawrocki, Sergiusz; Ciuleanu, Tudor-Eliade; Bosquée, Lionel; Trigo, José Manuel; Spira, Alexander; Tremblay, Lise; Nyman, Jan; Ramlau, Rodryg; Wickart-Johansson, Gun; Ellis, Peter; Gladkov, Oleg; Pereira, José Rodrigues; Eberhardt, Wilfried Ernst Erich; Helwig, Christoph; Schröder, Andreas; Shepherd, Frances A |
| 36 | 18-Nov-2013 | Lung cancer in Victoria: are we making progress? | Mitchell, Paul L R ; Thursfield, Vicky J; Ball, David L; Richardson, Gary E; Irving, Louis B; Torn-Broers, Yvonne; Giles, Graham G; Wright, Gavin M |
| 37 | 4-Nov-2013 | Should we screen for lung cancer in Australia? | Mitchell, Paul L R ; John, Thomas |
| 38 | 16-Oct-2013 | Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. | Liew, Mun Sem; Sia, Joseph; Starmans, Maud H W; Tafreshi, Ali; Harris, Sam; Feigen, Malcolm; White, Shane C; Zimet, Allan; Lambin, Philippe; Boutros, Paul C; Mitchell, Paul L R ; John, Thomas |
| 39 | 23-Jul-2013 | The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. | John, Thomas ; Starmans, Maud H W; Chen, Yao-Tseng; Russell, Prudence A; Barnett, Stephen A ; White, Shane C; Mitchell, Paul L R ; Walkiewicz, Marzena; Azad, Arun A; Lambin, Philippe; Tsao, Ming-Sound; Deb, Siddhartha; Altorki, Nasser; Wright, Gavin; Knight, Simon R ; Boutros, Paul C; Cebon, Jonathan S |
| 40 | 9-Jun-2012 | Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. | Scott, Andrew M ; Mitchell, Paul L R ; O'Keefe, Graeme J; Saunder, Timothy; Hicks, Rodney J; Poon, Aurora M T ; Baum, Charles; Brega, Nicoletta; McCarthy, Timothy J; Toner, Guy C |
Loading...
2
0
20
0
false